FDA releases draft guidelines on genome editing and CAR-T therapies
The US Food and Drug Administration (FDA) has issued draft guidance on the development of gene therapy products that incorporate genome editing of somatic cells and chimeric antigen receptor (CAR) T-cell products. The two draft guidance documents discuss the incorporation of genome editing and CAR-T product development.
More info: https://www.regmednet.com/fda-releases-draft-guidelines-on-genome-editing-and-car-t-therapies/
OpenEdition vous propose de citer ce billet de la manière suivante :
egennet (20 juillet 2022). FDA releases draft guidelines on genome editing and CAR-T therapies. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/o60s





